OCARINA Clinical Trial Program, Dose Selection and Non-Inferiority of Ocrelizumab Administered Subcutaneously in Patients with Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis

The requested reference [9954b2d66af87d1d613f77a3e4fb7b433d3a3af9] no longer exists in our database. It has been replaced by the current reference: [80e8966b59ae29e096012faf2520f210fce22764]

Authors
Category Primary study
ConferenceACTRIMS Forum 2024
Year 2024
This article has no abstract
Epistemonikos ID: 9e1019486e3f9943f7e48b181ae3e5b2e2e1b436
First added on: Dec 05, 2025